Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 2929Neoplasms 2624Lung Neoplasms 1366Colorectal Neoplasms 1328Prostatic Neoplasms 1214Carcinoma, Non-Small-Cell Lung 1079Carcinoma, Hepatocellular 782Stomach Neoplasms 720Pancreatic Neoplasms 701Ovarian Neoplasms 586Colonic Neoplasms 533Uterine Cervical Neoplasms 497Head and Neck Neoplasms 495Rectal Neoplasms 472Melanoma 467Multiple Myeloma 463Esophageal Neoplasms 422Neoplasm Metastasis 418Brain Neoplasms 404Lymphoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 397Urinary Bladder Neoplasms 386Leukemia, Myeloid, Acute 385Leukemia 339Carcinoma, Renal Cell 329Liver Neoplasms 320Endometrial Neoplasms 319Hematologic Neoplasms 312Recurrence 298Disease 272

Interventions

taletrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Non-small Lung Cancer × Clear all
NCT07199010 2025-09-30

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting
50 enrolled
Thoracic

Non-small Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡